Electra Therapeutics (NASDAQ:ETRA) Director Acquires 22,700 Shares of Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon bought 22,700 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was purchased at an average cost of $8.45 per share, with a total value of $191,815.00. Following the completion of the transaction, the director directly owned 5,255,278 shares in the company, valued at $44,407,099.10. This represents a 0.43% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Electra Therapeutics Stock Down 2.8%

ETRA stock traded down $0.23 during trading on Tuesday, reaching $7.99. 298,185 shares of the stock were exchanged, compared to its average volume of 376,388. Electra Therapeutics, Inc. has a twelve month low of $6.86 and a twelve month high of $15.50.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ETRA shares. HC Wainwright initiated coverage on Electra Therapeutics in a research report on Monday, October 26th. They set a “buy” rating and a $30.00 target price on the stock. JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics in a research report on Thursday, October 22nd. They issued an “overweight” rating and a $36.00 price target for the company. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research note on Wednesday, October 14th. Wall Street Zen upgraded shares of Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Finally, Jefferies Financial Group began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Electra Therapeutics has a consensus rating of “Buy” and a consensus target price of $33.50.

About Electra Therapeutics

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.